Chlamydia in Testicular Tissue Linked to Male Infertility
|
By LabMedica International staff writers Posted on 26 Oct 2019 |

Image: The histological detection of chlamydia in human testicular biopsies (Photo courtesy of Queensland University of Technology).
Infectious diseases, such as mumps virus infection of the human testis, are known to play a role in spermatogenic dysfunction and have been associated with abnormal sperm parameters. Bacteria including Escherichia coli, mycoplasmas and Chlamydia trachomatis in human semen are also associated with abnormal sperm parameters.
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
The potential impact of undiagnosed sexually transmitted chlamydia infection on men's fertility has been highlighted in a study, which for the first time found chlamydia in the testicular tissue biopsies of infertile men whose infertility had no identified cause. Challenges in attributing male infertility to chlamydia infection include a wide diversity in diagnostic approaches.
Biomedical scientists at the Queensland University of Technology (Herston, Australia) collected 100 diagnostic (fixed) and 18 therapeutic (fresh) human testicular biopsies during sperm recovery procedures from moderately to severely infertile men in a cross-sectional approach to sampling. Two chlamydial markers were detected: the general marker major outer membrane protein (MOMP) and the active replication marker TC0500. Sections of 4 μm were dewaxed and rehydrated using a Leica ST5010-CV5030 Integrated Workstation.
The slides were processed and staining was validated using primary antibody only, secondary antibody only and DAB only controls. Stained slides were scanned using Leica Biosystems’ Aperio AT Turbo. QIAamp DNA FFPE Tissue Kit was used to extract DNA from fixed biopsies. C. trachomatis 16S rRNA DNA was detected using real-time polymerase chain reaction. Serum samples matched to fresh biopsies were assayed for C. trachomatis-specific antibodies.
The scientists reported that Chlamydia was found in 43/95 men (45.3 %) of fixed testicular biopsies, and all the men in this group had no defined cause of infertility. Chlamydia was also found in 3/18 men (16.7 %) of fresh testicular biopsies, obtained during patient sperm recovery procedures. These three men, and another 10 in the group, had no identified cause for their infertility. In 12 of the 18 men providing the fresh biopsies (66.7%) Chlamydia trachomatis-specific antibodies were found in serum, indicating the men had been exposed to the bacteria, but all were asymptomatic and said they had not been diagnosed with any sexually transmitted infection.
Kenneth W. Beagley, PhD, a Professor of Immunology and a senior author of the study said, “Chlamydia infection has been associated with women's infertility but much less is known about its impact on male infertility, particularly if men do not experience symptoms, which is estimated to be in about 50% of cases. When people have no symptoms they can unknowingly pass on the infection to sexual partners. This is the first reported evidence of Chlamydia infection in human testicular tissue, and while it can't be said that Chlamydia was the cause of the infertility of the men, it is a significant finding. It reveals a high rate of previously unrecognized Chlamydia infection and the potential role of infection in the failure of sperm to develop in the testes.” The study was published on October 4, 2019, in the journal Human Reproduction.
Related Links:
Queensland University of Technology
Latest Microbiology News
- Gut Microbiome Signatures Help Identify Risk of IBD Progression
- FDA-Cleared Gastrointestinal Panel Detects 24 Pathogen Targets
- New AMR Assay Supports Rapid Infection Control Screening in Hospitals
- Diagnostic Gaps Complicate Bundibugyo Ebola Outbreak Response in Congo
- Study Finds Hidden Mpox Infections May Drive Ongoing Spread
- Large-Scale Genomic Surveillance Tracks Resistant Bacteria Across European Hospitals
- Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
- Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
- Label-Free Microscopy Method Enables Faster, Quantitative Detection of Malaria
- Oral–Gut Microbiome Signatures Identify Early Gastric Cancer
- Gut Microbiome Test Predicts Melanoma Recurrence After Surgery
- Rapid Blood-Culture Susceptibility Panel Expands Coverage for Gram-Negative Infections
- Antibiotic Resistance Genes Found in Newborns Within Hours of Birth
- Rapid Color Test Stratifies Virulent and Resistant Staph Strains
- mNGS CSF Test Identifies CNS Pathogens Missed by Standard Panels
- Syndromic Panel Enables Rapid Identification of Bloodstream Infections
Channels
Clinical Chemistry
view channel
Simple Dual-Tau Blood Test Detects and Stages Alzheimer’s Disease
Alzheimer’s disease is typically confirmed and staged with positron emission tomography scans and cerebrospinal fluid testing, procedures that are costly and invasive. Broader access to minimally invasive... Read more
Alzheimer’s Blood Biomarkers Linked to Early Cognitive Differences Before Dementia
Blood-based screening for Alzheimer’s disease offers a noninvasive, lower-cost alternative to brain imaging or spinal fluid testing, yet its ability to flag the earliest cognitive changes has been unclear.... Read moreMolecular Diagnostics
view channel
Genomic Test Guides Chemotherapy Decisions in Early-Stage Breast Cancer
Selecting adjuvant therapy for early-stage hormone receptor-positive breast cancer depends on accurately assessing long-term risk of distant recurrence. Clinical features alone can leave uncertainty about... Read more
Simple Cytogenetic Method Could Improve Classification of ALL Subtypes
Many cancers deviate from the normal chromosome number, but the clinical impact of extreme chromosome loss remains unclear. This widespread genomic disruption is associated with aggressive disease and... Read more
Blood-Based Assay Enables Noninvasive Monitoring of Sarcoma Immunotherapy Response
Sarcomas remain difficult to monitor during immunotherapy, as low tumor mutation burden can limit traditional circulating tumor DNA approaches and repeat tissue biopsies are often impractical in advanced disease.... Read moreHematology
view channel
Next-Generation Hematology Platform Streamlines High-Complexity Lab Workflows
Sysmex America (Chicago, IL, USA) has introduced the next generation XR-Series, centered on the XR-10 Automated Hematology Module for high-complexity laboratories. The platform builds on the widely used... Read more
Blood Eosinophil Count May Predict Cancer Immunotherapy Response and Toxicity
Immune checkpoint inhibitors have improved outcomes across many cancers, yet only a subset of patients derive durable benefit and biomarkers to guide treatment remain limited. Eosinophils, best known for... Read moreImmunology
view channel
Study Points to Autoimmune Pathway Behind Long COVID Symptoms
Long COVID leaves many SARS-CoV-2 survivors with persistent fatigue, cognitive issues, palpitations, and musculoskeletal pain for months or years. Estimates cited in new research suggest 4%–20% of infected... Read more
Metabolic Biomarker Distinguishes Latent from Active Tuberculosis and Tracks Treatment Response
Tuberculosis (TB) remains the world’s leading infectious killer, with 10.8 million cases and 1.25 million deaths recorded globally in 2023. Yet many infected individuals never develop active disease, underscoring... Read morePathology
view channel
Blood-Based Method Tracks Gene Activity in the Living Brain
Real-time measurement of gene activity in the brain has been limited by assays requiring destructive tissue sampling. Tracking active genes could reveal how the body responds to environmental factors,... Read more
FDA Approval Expands Automated PD-L1 Testing Across Solid Tumors
Clinical laboratories play a central role in guiding immunotherapy by reporting programmed death ligand-1 (PD‑L1) status across multiple solid tumors. Many sites are standardizing this work on fully automated... Read moreTechnology
view channel
AI Platform Links Biomarker Results to Cancer Clinical Trials and Guidelines
Oncology teams must manage growing volumes of genomic data, rapidly evolving clinical trial options, and frequently updated care guidelines, all within tight clinic schedules. Translating complex tumor... Read more
Agentic AI Platform Supports Genomic Decision-Making in Oncology
Oncology care teams increasingly face the challenge of managing complex molecular diagnostics, evolving treatment options, and extensive electronic health record documentation. Translating multimodal data... Read moreIndustry
view channel








